Market news

electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel. On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference. Investors who wish to reques

Internal leadership appointments reflect the Company's confidence in two exceptional leaders whose complementary strengths will enhance shareholder valueROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, ef

Recognition highlights Truvaga’s combination of patented non-invasive vagus nerve stimulation technology, thoughtful design and personalized wellness experienceROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic technology company, today announced that Truvaga, its non-invasive vagus nerve stimulation (nVNS) wellness brand, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The award recognizes T

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Co

ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences: Needham 11th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Tuesday, August 11, 2026. Management will host one-on-one meetings virtually.Canaccord Genuity 46th Annual Growth Conference, taking place in Boston, Massachusetts, on Tuesda

ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, August 6, 4:30 PM EDTDial-I

ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical